You are here

Article Text

Article menu
Download PDFPDF
Short report
Global burden of vaccine-associated uveitis and their related vaccines, 1967–2023
  1. Jiyeon Oh1,2,
  2. Seoyoung Park2,
  3. Jaeyu Park2,3,
  4. Hyesu Jo2,3,
  5. Hayeon Lee2,
  6. Raphael Udeh4,
  7. Masoud Rahmati5,6,7,
  8. Jee Myung Yang8,
  9. Joo Yong Lee8,
  10. Dong Keon Yon1,2,3
  1. 1 Department of Medicine, Kyung Hee University College of Medicine, Seoul, Korea (the Republic of)
  2. 2 Center for Digital Health, Kyung Hee University College of Medicine, Seoul, Korea (the Republic of)
  3. 3 Department of Regulatory Science, Kyung Hee University, Seoul, Korea (the Republic of)
  4. 4 School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, Australia
  5. 5 Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khurramabad, Iran
  6. 6 Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran
  7. 7 CEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
  8. 8 Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
  1. Correspondence to Professor Jee Myung Yang; jeemang87{at}gmail.com; Professor Joo Yong Lee; jylee.retina{at}gmail.com; Professor Dong Keon Yon; yonkkang{at}gmail.com

Abstract

Although uveitis after vaccination is rare, reports emerged during the COVID-19 pandemic. We used the pharmacovigilance case/non-case study from 1967 to 2023 to assess the association between vaccines and uveitis. We identified a significant signal for uveitis (reporting OR (ROR), 1.64; information component (IC)025, 0.66) with 1508 reports. This association is pronounced in females of all ages after childhood. Specifically, the COVID-19 messenger RNA vaccines showed the strongest disproportionality signal (ROR, 5.76; IC025, 2.33), followed by hepatitis B, papillomavirus, Ad (Adenovirus) 5-vectored COVID-19 and influenza vaccines. These findings underscore the importance of surveillance in the postmarketing phase to manage potential adverse events associated with vaccine administration.

  • Uveitis
  • Epidemiology

Data availability statement

The data are available upon request. Study protocol and statistical code: Available from DKY (yonkkang@gmail.com). Data set: Available from the Uppsala Monitoring Centre or WHO through a data use agreement.

https://doi.org/10.1136/bjo-2024-325985

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    The data are available upon request. Study protocol and statistical code: Available from DKY (yonkkang@gmail.com). Data set: Available from the Uppsala Monitoring Centre or WHO through a data use agreement.

    View Full Text

    Footnotes

    • JO, SP and JP are joint first authors.

    • Contributors DKY had full access to all data in the study and took responsibility for data integrity and analysis accuracy. All authors have approved the final version of the manuscript before submission. Study concept and design: JO, SP, JP and DKY; Acquisition, analysis or interpretation of data: JO, SP, JP and DKY; Drafting of the manuscript: JO, SP, JP and DKY; Critical revision of the manuscript for important intellectual content: All authors; Statistical analysis: JO, SP, JP and DKY; Study supervision: JMY, JYL and DKY. DKY supervised the study and served as the guarantor. JO, SP and JP contributed equally as the first authors. JMY, JYL and DKY contributed equally to this study as corresponding authors. DKY is the senior author. The corresponding author attests that all listed authors meet the authorship criteria and none meeting the criteria have been omitted. DKY contributed as senior author.

    • Funding This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT; RS-2023-00248157) and the Global Physician-scientist programme funded by the Ministry of Health and Welfare of Korea (RS-2024-00405141). The funders played no role in the study design, data collection, analysis, interpretation or manuscript writing.

    • Map disclaimer The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.